共 50 条
- [31] Real-world clinical outcomes and healthcare costs in patients with Crohn's disease treated with vedolizumab versus ustekinumab in the United StatesCURRENT MEDICAL RESEARCH AND OPINION, 2024, 40 (05) : 877 - 885Chiorean, MichaelJiang, JeanneCandela, NinfaChen, GraceRomdhani, HelaLatremouille-Viau, DominickShi, SherryBungay, RebeccaGuerin, AnnieFan, Tao
- [32] Adalimumab maintains clinical remission and response in patients with active Crohn's disease: Results of the CHARM trialAMERICAN JOURNAL OF GASTROENTEROLOGY, 2006, 101 (09): : S458 - S458Sandborn, William J.Colombel, J. F.Rutgeerts, P.Enns, R.Hanauer, S. B.Panaccione, R.Schreiber, S.Lomax, K. G.Pollack, P. F.
- [33] NUMBER NEEDED TO TREAT TO ACHIEVE CLINICAL RESPONSE AT WEEK 8 ALONG WITH RESPONSE OR REMISSION AT WEEK 52 WITH USTEKINUMAB TREATMENT VS PLACEBO FROM THE PHASE 3 UNITI CROHN'S DISEASE STUDIES, BY POPULATIONGASTROENTEROLOGY, 2018, 154 (06) : S391 - S391Ghosh, SubrataGasink, ChristopherGao, Long-LongObando, Camilo
- [34] Number needed to treat to achieve clinical response at week 8 along with response or remission at week 52 with ustekinumab treatment vs. placebo from the phase 3 UNITI Crohn's disease studies, by populationJOURNAL OF CROHNS & COLITIS, 2018, 12 : S450 - S451Ghosh, S.Gasink, C.Gao, L. -L.Obando, C.
- [35] Crohn's Disease Patients Who Do Not Qualify for Clinical Trials Have Similar Clinical and Endoscopic Response Rates to Ustekinumab to Those Who Qualify for Clinical TrialsAMERICAN JOURNAL OF GASTROENTEROLOGY, 2019, 114 : S432 - S433Cohen, Erica R.Syal, GauravHa, Christina
- [36] Risankizumab Versus Ustekinumab for the Achievement of Clinical Outcomes and Symptom Improvement in Patients With Moderate To Severe Crohn's Disease: Results From the Phase 3b SEQUENCE TrialJOURNAL OF CROHNS & COLITIS, 2024, 18 : I65 - I66Dubinsky, M. C.D'Haens, G.Atreya, R.Abraham, B.Armuzzi, A.Arguelles-Arias, F.Lindsay, J. O.Patel, K.Neimark, E.Huang, X.Anschutz, T.van Haaren, S.O'Brien, D.Ferrante, M.
- [37] Adalimumab induces and maintains clinical response and remission in patients with active Crohn's disease: Results of the CHARM TrialGASTROENTEROLOGY, 2006, 131 (03) : 950 - 950Colombel, J.Sandborn, W. J.Rutgeerts, P.Enns, R.Hanauer, S. B.Remo, P.Schreiber, S.Lomax, K. G.Pollack, P. F.
- [38] Pharmacokinetics, Exposure-Response Relationships, and Immunogenicity in Crohn's Disease Patients With Ustekinumab Secondary Loss of Response Following Ustekinumab IV Re-Induction: Week 16 Results From the POWER StudyAMERICAN JOURNAL OF GASTROENTEROLOGY, 2023, 118 (10): : S622 - S622Feagan, Brian G.Lee, Scott D.van der Woude, C. JannekeMarin-Jimenez, IgnacioWolf, Douglas C.Schnoy, ElisabethSalzberg, BruceBusse, ChristopherNazar, MaciejLangholff, WayneGasink, ChristopherBaker, ThomasGodwin, BridgetAdedokun, OmoniyiSchreiber, Stefan
- [39] Analysis of Baseline Characteristics Associated With Clinical Response to Ustekinumab IV Re-Induction Strategy in Patients With Crohn's Disease in the POWER TrialAMERICAN JOURNAL OF GASTROENTEROLOGY, 2023, 118 (10): : S786 - S786Wolf, Douglas C.Lee, Scott D.Schreiber, Stefanvan der Woude, C. JannekeMarin-Jimenez, IgnacioSchnoy, ElisabethSalzberg, BruceBusse, ChristopherNazar, MaciejLangholff, WayneGasink, ChristopherBaker, ThomasGodwin, BridgetFeagan, Brian G.
- [40] Crohn's Disease Strictures Respond to Drug Treatment and Treat-to-Target Intense Combination Therapy is More Effective than Standard Anti-TNF Therapy. Two year results of the STRIDENT Randomised Controlled TrialJOURNAL OF CROHNS & COLITIS, 2023, 17 : I160 - I161Schulberg, J.Hamilton, A.Wright, E. K.Holt, B.Lovett, G.Sutherland, T.Ross, A.Vogrin, S.Kamm, M.